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Abstract
Background: Many national and international guidelines recommend that the initiation of blood pressure (BP)-lowering drug
treatment for the primary prevention of cardiovascular disease (CVD) should no longer be based on BP level alone, but on absolute
cardiovascular risk. While BP-lowering drug treatment is beneficial in high-risk individuals at any level of elevated BP, clinicians
are concerned about legacy effects on patients with low-to-moderate risk and mildly elevated BP who remain “untreated”.
Objective: We aim to investigate the legacy effect of delayed BP-lowering pharmacotherapy in middle-aged individuals (45-65
years) with mildly elevated BP (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg) stratified by absolute risk for
primary prevention of CVD, but particularly in the low-risk (<10% five-year absolute risk) group.
Methods: Randomized trials of BP-lowering therapy versus placebo or pretreated subjects in active comparator studies with
posttrial follow-up will be identified using a 2-step process. First, randomized trials of BP-lowering therapy will be identified by
(1) retrieving the references of trials included in published systematic reviews of BP-lowering therapy, (2) retrieving studies
published by the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC), and (3) checking studies referenced
in the 1993 World Health Organization/International Society of Hypertension meeting memorandum on BP management. Posttrial
follow-up studies will then be identified by forward citation searching the randomized trials identified in step 1 through Web of
Science. The search will include randomized controlled trials with at least 1-year in-trial period and a posttrial follow-up phase.
Age is the major determinant of absolute cardiovascular risk, so the participants in our review will be restricted to middle-aged
adults who are more likely to have a lower cardiovascular risk profile. The primary outcome will be all-cause mortality. Secondary
outcomes will include cardiovascular mortality, fatal stroke, fatal myocardial infarction, and death due to heart failure.
Results: The searches for existing systematic reviews and BPLTTC studies were piloted and modified. The study is expected
to be completed before June 2018.
Conclusions: The findings of this study will contribute to the body of knowledge concerning the beneficial, neutral, or harmful
effects of delayed BP-lowering drug treatment on the primary prevention of CVD in patients with mildly elevated BP and
low-to-moderate CVD risk.
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Trial Registration: PROSPERO International Prospective Register of Systematic Reviews: CRD42017058414;
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Introduction
Despite improvements in the management of cardiovascular
disease (CVD) over the past five decades, it remains the leading
cause of death and disability in the world [1]. CVD was
responsible for approximately 17.5 million deaths worldwide
in 2012 [1]. In updated guidelines for the primary prevention
of CVD from Australasia [2,3], the United Kingdom [4], and
Europe [5], blood pressure (BP)-lowering pharmacotherapy is
indicated by absolute CVD risk, not BP level alone. In contrast,
the US guideline (the Eighth Joint National Committee) [6] is
still heavily focused on BP level and age, despite the fact that
BP-lowering therapy is beneficial for the reduction of CVD
mortality and morbidity at sufficiently high CVD absolute risk,
regardless of the level of BP elevation [7]. The use of
BP-lowering drug treatment in high-risk settings has achieved
consensus in Australasian [2,3], European [5], and the US
guidelines [6]. In low-risk individuals, BP-lowering drugs are
not recommended by guidelines in Australia [2], New Zealand
[3] or the United Kingdom [4], unless BP exceeds a level of
160/100 mmHg, whereas the European [5] and US [6] guidelines
recommended an early initiation at a BP level of 140/90 mmHg.
However, both approaches raised many concerns from clinicians
and a gap still exists between guidelines and clinical practice
[8].
An international expert consultation was recently performed to
solve the controversy of whether adults with grade 1
hypertension (<140/90 mmHg) and low-to-moderate CVD risk
should be treated by drug therapy [9]. Morales-Salinas et al [9]
recommended an early initiation of BP-lowering
pharmacotherapy primarily from the results of the Heart
Outcomes Prevention Evaluation (HOPE-3) trial [10] and a
meta-analysis by Thomopoulos et al [11] for adults with grade
1 hypertension and moderate CVD risk; however, the two
studies were likely to include a number of high-risk participants.
In the HOPE-3 trial [10], participants with an INTERHEART
risk score higher than 16 (a value of 16 or higher indicates a
high CVD risk) accounted for 32.5% of the total sample [12].
In the meta-analysis by Thomopoulos et al [11], the CVD risk
was calculated by CVD death rate in the control group, while
the CVD risk score used in most guidelines is for fatal and
nonfatal CVD events. Thus, the benefits of BP-lowering
pharmacotherapy in low-to-moderate-risk individuals remain
unclear, as opposed to the benefits achieved by treating high
risk individuals. Most clinicians use BP-lowering
pharmacotherapy based on BP criteria alone, due to the
perceived potential risk of irreversible target organ damage (the
“legacy effect”) for delayed therapy [5]. Studies that would help
us to answer this question include those that have extended
follow-up in the posttrial period. Such studies include the
Systolic Hypertension in the Elderly Program trial [13] of
approximately 22 years, the Hypertension Detection and
Follow-Up Program [14] of 8.3 years, and the second Australian
National Blood Pressure study [15] of 10.6 years. Participants
in these studies are still likely to be at high baseline risk of CVD
due to the advanced age and diabetic status in the inclusion
criteria of the trials [13-15]. Hence, the concern of legacy effects
on low-to-moderate-risk individuals has not been addressed.
Age is the most important determinant of adverse cardiovascular
risk, so the participants in our review are restricted to
middle-aged adults who are more likely to have a broader
cardiovascular risk profile. Therefore, in this systematic review
and meta-analysis, we will investigate the effects of BP-lowering
drug treatments in middle-aged individuals with mildly elevated
BP, stratified by absolute CVD risk.
Methods
Review Objectives
Aim 1
We will conduct a systematic review and meta-analysis of
published and unpublished studies of randomized placebo
control trials with a posttrial follow-up phase that included
middle-aged participants without overt CVD, and examine these
studies for CVD mortality and all-cause mortality.
Aim 2
We will conduct a subgroup analysis (where possible) of
participants in these trials classified as low-, moderate-, and
high-absolute CVD risk by the Framingham Risk Score (FRS)
used in the Australia guideline [2], or the risk calculator used
by the Blood Pressure Lowering Treatment Trialists’
Collaboration (BPLTTC) [16] which uses routine clinical
information if information on cholesterol levels is not available
for fatal and nonfatal CVD events and all-cause mortality. We
will conduct an individual patient data meta-analysis, if data
are available.
Primary Null Hypothesis
There will be no significant difference in CVD mortality or
all-cause mortality between patients who have drug therapy
initiated earlier (active treatment arm) versus delayed or not
initiated (control arm) in individuals at low-absolute CVD risk.
Secondary Hypotheses
Hypothesis 1
There will be no significant difference in CVD mortality or
all-cause mortality between patients who have drug therapy
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initiated earlier (active treatment arm) versus delayed or not
initiated (control arm) in individuals at moderate-absolute CVD
risk.
Hypothesis 2
There will be no significant difference in CVD mortality or
all-cause mortality between patients who have drug therapy
initiated earlier (active treatment arm) versus delayed or not
initiated (control arm) in individuals at high-absolute CVD risk.
Hypothesis 3
In-trial CVD events (fatal and nonfatal) will be incremental by
risk classification estimated by FRS or equivalent risk calculated
at baseline.
Criteria for Considering Studies in the Review
Population
The study will include men and nonpregnant women from 45
to 65 years of age. At least 80% of participants from each trial
must have had mildly elevated BP at baseline, defined as a
systolic BP of 140- 159 mmHg and/or diastolic BP 90- 99
mmHg. Furthermore, all included participants must not have
exhibited any history of CVD at baseline: myocardial infarction,
angina pectoris, coronary bypass surgery, coronary angioplasty,
stroke, transient ischaemic attack, carotid endarterectomy,
surgery for peripheral vascular disease, intermittent claudication
or renal failure (creatinine >1.5 times the upper limit of normal).
If trials included participants different than those of interest (eg,
secondary prevention, moderately-elevated or highly-elevated
BP), we will attempt to access individual patient data and
subsequently select participants that meet specific criteria.
Intervention
The study will focus on all types of BP-lowering drugs, except
for some types that have limited clinical use due to the risk of
side effects and availability (eg, ganglion blockers, reserpine,
rauwolfia).
Comparison
The study will compare the effects of BP-lowering drug
treatments in active treatment groups versus control treatment
groups. However, if comparative trials with two active
comparators had an extended posttrial follow-up phase and
individual data are available, we will perform a legacy effect
analysis per Nelson et al [15]. We will reclassify participants
into previous treatment (early treatment) groups and treatment
naïve (delayed treatment) groups. The previous treatment group
will include participants who were on BP-lowering drug
treatments at trial registration and then went on a specific drug
withdrawal program. The treatment naïve group will include
those who were not on any treatments at trial registration.
Outcomes
Primary outcomes will include all-cause mortality in both
randomization and follow-up periods. Secondary outcomes will
include CVD mortality (defined as deaths due to stroke,
myocardial infarction, and heart failure), fatal stroke, fatal
myocardial infarction, and fatal heart failure. Nonfatal CVD
events will be included if the measurements of outcomes are
similar between trials. Vital status in posttrial periods must be
assessed by national death databases or equivalent records.
Study Design
Randomized controlled trials with at least 1-year in-trial period
and a posttrial follow-up phase.
Language
No restriction (English and non-English studies).
Publication Type
Published and unpublished studies reported in peer-reviewed
journals, reports, conference abstracts, and theses.
Search Methods for Identification of Studies
Randomized trials of BP-lowering therapies versus placebo or
active comparator with posttrial follow-up periods will be
identified using a 2-step process. First, randomized trials of
BP-lowering therapy will be identified by (1) retrieving the
references of trials included in published systematic reviews of
BP-lowering therapy, (2) retrieving studies published by the
BPLTTC, and (3) checking studies referenced in the 1993
WHO/ISH (World Health Organization/International Society
of Hypertension) meeting memorandum on BP management
[17]. To identify existing systematic reviews, we will search
Medline Ovid using a combination of Medical Subject Headings
and text word terms for BP-lowering regimes and high BP with
a systematic review filter (see Multimedia Appendix 1). Web
of Science will be used to retrieve the references of studies cited
by the systematic reviews, and these will be exported to an
Endnote file. To identify studies from the BPLTTC, a text word
search in the title, abstract, and author fields will be conducted
in Ovid Medline and the retrieved references will be exported
to the Endnote file. Web of Science will be used to retrieve the
references of studies cited in the WHO/ISH meeting
memorandum and these will be exported to the Endnote file.
After removing duplications, the Endnote file will be screened
to identify randomized trials of BP-lowering therapies versus
placebo or active comparators. In the second step of the search,
posttrial follow-up studies will be identified by forward citation
searching the randomized trials identified in step 1. Web of
Science will be used for forward citation searches of each of
the original trials, with the citations exported to another Endnote
file. After the removal of duplications in the Endnote file, the
file will be searched using terms related to extended follow-up
(see Multimedia Appendix 2). The resulting titles and abstracts
will be screened independently by two reviewers using the
review eligibility criteria.
Study Selection
First, two independent reviewers will screen a small sample of
papers found in the search to revise any unclear or inappropriate
inclusion criteria. In the full selection process, two reviewers
will independently scan the results of the search and determine
the eligibility of the studies. In the initial screening of titles and
abstracts, the studies will be included if they meet the inclusion
criteria or they do not have enough information for exclusion.
Rejected citations will be recorded and classified as irrelevant
studies. All potentially relevant articles will be screened through
full text for a final decision. If a paper does not have sufficient
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information to assess eligibility, we will attempt to contact the
authors; the paper will be classified as a potentially relevant
article and checked in sensitivity analyses if authors do not
reply after one month. If we identify trials that meet our
inclusion criteria but lack data on the posttrial follow-up period,
we will run a forward citation search from those studies. If a
study has multiple citations, we will report separate citations
but analyze these reports as a single study. We will also liaise
with the BPLTTC for any individual patient data from trials
meeting our inclusion criteria.
Data Extraction and Quality Assessment
Data extraction forms (detailed in Textbox 1) and quality
assessment forms will be piloted on a small group of studies.
Two reviewers will independently perform data extraction and
quality assessment in the prespecified form. If any disagreements
arise, the reviewers will discuss consensus or consult with the
third reviewer. A report of correction or amendments to the
prespecified form will be recorded.
Textbox 1. Information required for data extraction.
General information: reviewer performing data extraction, date of data extraction, and identification features of the study (eg, record number, authors,
article title, type of publication, country of origin, the source of funding)
Study characteristics: aims of the study, study design, study inclusion and exclusion criteria, recruitment procedures (details of randomization,
blinding), and unit of allocation (participant, GP practice)
Participant characteristics: baseline characteristics (age, gender, ethnicity, socioeconomic status, comorbidities, systolic BP, diastolic BP, weight,
height, smoking status, serum total cholesterol, serum creatinine level), and the number of participants in active treatment group and control group
Intervention and setting: type and dose of BP-lowering regimen
Outcome data:
• For each outcome: whether reported, definition, length of follow-up, number of events, number of participants in each event, odds ratio, risk
ratio, and hazard ratio
• For both intervention groups: number of participants enrolled; number of participants included in analysis; and number of withdrawals, exclusions,
and lost to follow-up
Type of analysis used in the study: intention to treat or per protocol
Quality Assessment
The risk of bias will be assessed by two reviewers following
the Cochrane Risk of bias tool [18] which includes the following
criteria: random sequence generation (selection bias); allocation
concealment (selection bias); blinding of participants, personnel,
and outcome (performance and detection bias); and incomplete
outcome data (attrition bias). The bias will be assessed as
unclear, low-risk, or high-risk. Publication bias will be judged
by observing the asymmetry of funnel plots; if they are
asymmetric, contour-enhanced funnel plots will then be analyzed
to examine whether publication bias alone caused the
asymmetry. We will also use Egger’s meta-regression model
to assess the relationship between the observed effect sizes and
the size of studies [19].
Data Synthesis and Analysis
After pooling all eligible studies, we will design a fixed-effect
model and assess the heterogeneity by visually inspecting the
forest plots, Chi-squared tests, and I2tests. Statistical
heterogeneity will be recorded when the studies’ confidence
intervals exhibit poor overlap, the P-value of the test of
heterogeneity is 0.1 or lower, or the I2value is 0.5 or greater. In
these cases, we will also perform an analysis using a
random-effects model. All trial endpoints will be treated as
dichotomous variables and grouped by time from randomization.
In the fixed-effect model, the Mantel-Haenszel method model
will be used to combine risk ratios of each outcome [20]. We
will conduct a subgroup analysis in which available risk
calculators will be used to stratify participants by the baseline
absolute CVD risk for fatal and nonfatal CVD events. In a
sensitivity analysis, each study will be removed (one at a time)
to assess the impact of each study on the pooled outcomes. The
Cochrane software (Revman) [21] will be used for
meta-analysis, selective reporting, and other sources of bias.
Ethics and Dissemination
This systematic review will analyze nonidentifiable data; thus,
a formal ethics approval is unlikely to be crucial. The study
protocol was registered with the International Prospective
Register of Systematic Review (PROSPERO) with the reference
number CRD42017058414. The current study will contribute
a chapter of a PhD thesis (CH).
Results
We are currently in the process of developing the search
strategy. The search in Medline via Ovid has been piloted and
modified. The analysis is expected to complete before June
2018.
Discussion
Given the strong beliefs held by many clinicians that early
treatment of elevated BP is necessary to prevent CVD events,
it is not possible to conduct a randomized controlled trial of
early versus late treatment at present. This is particularly true
for patients with mildly elevated BP and low CVD risk, as
studies would require a large sample size of participants or a
long follow-up period because approximately 10% of CVD
events are expected to occur within 10 years. In addition,
clinicians are questioning the real benefits, adverse effects, and
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medical costs of the life-long intervention of BP-lowering drug
treatment. The findings of this study will contribute to the body
of knowledge concerning the beneficial, neutral, or harmful
effects of delayed BP-lowering drug treatment in patients with
mildly elevated BP and low-to-moderate CVD risk.
Limitations
Due to the changes in definitions of CVD and diagnostic
methods used over time, we predict that it will be difficult to
combine these outcomes in a meta-analysis. This issue inherently
generates bias in selection, detection, attrition, and reporting.
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